Clinically, ganetespib shows a good safety profile with no dose-limiting liver organ or ocular toxicities connected with other Hsp90 inhibitors [20,21], and shows encouraging activity within a Phase 2 NSCLC trial [22]
Clinically, ganetespib shows a good safety profile with no dose-limiting liver organ or ocular toxicities connected with other Hsp90 inhibitors [20,21], and shows encouraging activity… Read More »Clinically, ganetespib shows a good safety profile with no dose-limiting liver organ or ocular toxicities connected with other Hsp90 inhibitors [20,21], and shows encouraging activity within a Phase 2 NSCLC trial [22]